Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026
The Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Gastrointestinal Stromal Tumor (GIST) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
GASTROINTESTINAL STROMAL TUMOR PIPELINE ANALYSIS
• Gastrointestinal stromal tumors (GISTs) have been endorsed as a biologically peculiar but superior tumor type, different from neural tumors and smooth muscle of the digestive tract (GIT).
• They rule a significant part of gastrointestinal mesenchymal tumors of the GIT and are known to be refractory to conventional chemotherapy or radiation.
• They are both defined and interpreted by the expression of a proto-oncogene protein detected by immunohistochemistry, which serves as a vital diagnostic and therapeutic target.
• Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms in the digestive tract, which, over the last ten years, have emerged from a poorly understood neoplasm to a distinct tumor entity exhibiting molecular abnormalities and for which promising novel treatment modalities have been developed.
• The story of GIST is unique in that targeted molecular therapy was successfully applied in clinical therapeutics, with dramatic results redefining the management of these traditionally chemotherapy-resistant tumors.
• Among the pipeline drugs in mid- to late stage development for GIST most of them are administered via the oral route. Sutent’s (sunitinib) US patents are set to expire in December 2020, which will open the door to generic entry. The distribution of clinical trials across Phases I-IV indicates that majority of tests for GIST have been in early and mid phases of development, with 82.7% of trials in Phase I-II and only 17.3% in Phase III.
• The US has a considerable lead in the number of GIST clinical trials globally. Completed tests dominate the clinical trial activity in the GIS space.
• Novartis leads industry sponsors with the highest number of clinical trials for GIST. Bayer’s regorafenib (StivargaTM) is in the market with fluctuating sales in recent years. Avapritinib of Blueprint Medicines is in late-stage of development. Amcasertib of Boston Medical is in the Phase 2 stage of development while Intuvax of Immunicum is in Phase 1/2 clinical trial.
• From last few years, many institutes and companies have teamed up for developing therapeutics treating gastrointestinal stromal tumor (GIST).
• There are seven emerging firms in the gastrointestinal stromal tumor (GIST), which are eager in seeking an alliance for development opportunities for the maximization of their technology as well as the business platform.
• Among companies dealing with gastrointestinal stromal tumor (GIST) technology, Juno Therapeutics has maidened in the field of collaborations with five collaborations with other companies and three partnerships with universities for the products and technology in recent years. Novartis is the leading company with the positive results of their Gastrointestinal Stromal Tumor (GIST) therapy is pushed ahead with the new clinical trials.
• Gastrointestinal stromal tumors (GISTs) have been endorsed as a biologically peculiar but superior tumor type, different from neural tumors and smooth muscle of the digestive tract (GIT).
• They rule a significant part of gastrointestinal mesenchymal tumors of the GIT and are known to be refractory to conventional chemotherapy or radiation.
• They are both defined and interpreted by the expression of a proto-oncogene protein detected by immunohistochemistry, which serves as a vital diagnostic and therapeutic target.
• Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms in the digestive tract, which, over the last ten years, have emerged from a poorly understood neoplasm to a distinct tumor entity exhibiting molecular abnormalities and for which promising novel treatment modalities have been developed.
• The story of GIST is unique in that targeted molecular therapy was successfully applied in clinical therapeutics, with dramatic results redefining the management of these traditionally chemotherapy-resistant tumors.
• Among the pipeline drugs in mid- to late stage development for GIST most of them are administered via the oral route. Sutent’s (sunitinib) US patents are set to expire in December 2020, which will open the door to generic entry. The distribution of clinical trials across Phases I-IV indicates that majority of tests for GIST have been in early and mid phases of development, with 82.7% of trials in Phase I-II and only 17.3% in Phase III.
• The US has a considerable lead in the number of GIST clinical trials globally. Completed tests dominate the clinical trial activity in the GIS space.
• Novartis leads industry sponsors with the highest number of clinical trials for GIST. Bayer’s regorafenib (StivargaTM) is in the market with fluctuating sales in recent years. Avapritinib of Blueprint Medicines is in late-stage of development. Amcasertib of Boston Medical is in the Phase 2 stage of development while Intuvax of Immunicum is in Phase 1/2 clinical trial.
• From last few years, many institutes and companies have teamed up for developing therapeutics treating gastrointestinal stromal tumor (GIST).
• There are seven emerging firms in the gastrointestinal stromal tumor (GIST), which are eager in seeking an alliance for development opportunities for the maximization of their technology as well as the business platform.
• Among companies dealing with gastrointestinal stromal tumor (GIST) technology, Juno Therapeutics has maidened in the field of collaborations with five collaborations with other companies and three partnerships with universities for the products and technology in recent years. Novartis is the leading company with the positive results of their Gastrointestinal Stromal Tumor (GIST) therapy is pushed ahead with the new clinical trials.
